In this work, authors develop obex inhibitors that target a distinct binding pocket in the ATPase domain of Topoisomerase II. They demonstrate how Topobexin, a Topoisomerase IIβ - selective catalytic inhibitor, blocks conformational changes and protects against anthracycline cardiotoxicity.
- Jan Kubeš
- Galina Karabanovich
- Matthew J. Schellenberg
